Rice Hall James & Associates LLC Purchases New Shares in Repligen Co. (NASDAQ:RGEN)

Rice Hall James & Associates LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 15,391 shares of the biotechnology company’s stock, valued at approximately $2,215,000.

A number of other hedge funds also recently bought and sold shares of the business. Ballentine Partners LLC raised its stake in Repligen by 4.0% during the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock valued at $270,000 after purchasing an additional 72 shares in the last quarter. CIBC Asset Management Inc raised its stake in Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock valued at $246,000 after purchasing an additional 81 shares in the last quarter. MML Investors Services LLC raised its stake in Repligen by 2.7% during the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after purchasing an additional 89 shares in the last quarter. GAMMA Investing LLC raised its stake in Repligen by 15.2% during the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 90 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its stake in Repligen by 0.7% during the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock valued at $2,087,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Down 1.2 %

NASDAQ RGEN opened at $145.18 on Wednesday. The company’s 50-day moving average price is $155.26 and its 200-day moving average price is $148.82. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $207.87.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on RGEN shares. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. HC Wainwright reduced their target price on shares of Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. TD Cowen started coverage on shares of Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. Wolfe Research started coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. Finally, Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $182.91.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.